Compare iShares China Large-Cap ETF (FXI) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Gilead Sciences, Inc. — how do they compare? iShares China Large-Cap ETF trades at $34.53, while Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B). The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares China Large-Cap ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | GILD | |
|---|---|---|
52-Week High | $41.75 | $155.80 |
52-Week Low | $31.59 | $108.22 |
Market Cap | — | $163.51B |
Sector | — | Health |
Enterprise Value | — | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares China Large-Cap ETF (FXI) trades at $34.535, up 2.27% on the day, with technical indicators showing a bullish overall signal despite some overbought RSI readings. Recent news highlights China's significant push into AI and electric vehicles, including a reported $295 billion AI infrastructure plan and a 30% NEV fleet target by 2030, which could benefit the large-cap Chinese companies held within the fund.
The outlook for FXI is tied to China's economic policy execution and its success in strategic sectors like AI and EVs. Key opportunities include exposure to state-backed industrial and tech giants, while risks stem from U.S.-China tech rivalry, regulatory shifts, and the potential for Chinese equities to act as a value trap despite apparent undervaluation.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
